Societe Generale Gives Buy Rating to GlaxoSmithKline (GSK)
GSK has been the subject of a number of other recent research reports. Analysts at Sanford C. Bernstein reiterated a “market perform” rating on shares of GlaxoSmithKline in a research note to investors on Monday, October 15th. They now have a $24.24 price target on the stock. Separately, analysts at Jefferies Group reiterated a “hold” rating on shares of GlaxoSmithKline in a research note to investors on Friday, October 12th. They now have a $23.59 price target on the stock. Finally, analysts at Liberum Capital Ltd reiterated an “underweight” rating on shares of GlaxoSmithKline in a research note to investors on Friday, October 5th. They now have a $22.34 price target on the stock.
GlaxoSmithKline opened at 1407.50 on Thursday. GlaxoSmithKline has a 1-year low of GBX 1321.00 and a 1-year high of GBX 1556.50. The company’s market cap is £69.108 billion.
GlaxoSmithKline plc (GSK) is global healthcare group, which is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.